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Conclusion: In total 60 of 94 pts (63.8%) with homogenously 
pT3a pN0/cN0 R1 resected PCA received radiotherapy 
highlighting the need of adjuvant/salvage treatment in those 
pts. The efficacy of radiotherapy is documented by the fact 
that the median PSA of all irradiated pts at 80 months of 
follow up was 0.01ng/ml (0.0 – 204.9). This may be blurred 
by the influence of ADT (15 pts). However, even our small 
retrospective cohort demonstrates a biochemical recurrence 
rate of originally postoperatively PSA negative pts of 49.2%. 
Furthermore, 65.7% of these pts could be rendered at least 
temporarily PSA-free by postoperative radiation.  
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Purpose or Objective: Aim of this study was to evaluate the 
safety, in terms of acute and late toxicity and QoL in patients 
(pts) with prostate carcinoma (PCa) treated with moderately 
hypofractionated IGRT/IMRT-SIB using fiducial markers.  
 
Material and Methods: Three-hundred consecutive PCa pts 
were treated with daily on-line IGRT based on 2D (6MV) 
orthogonal images. Low risk pts received 62.1 Gy in 23 
fractions to PTV1 (prostate). Intermediate risk pts with 
probability < 15% of lymph nodes involvement (Roach’s 
equation) received 67.5 Gy and 56.25 Gy in 25 fractions to 
PTV1 and PTV2 (seminal vesicles). In high risk patients with 
probability > 15% of lymph nodes involvement, pelvic lymph 
nodes (PTV3) received 50 Gy. Acute and late toxicities were 
prospectively recorded using RTOG-EORTC scale and AUA 
score. Survival curves were calculated using the Kaplan-Meier 
method. Androgen suppressive therapy was prescribed based 
on risk categories.  
 
Results: GI and GU G ≥ 3 acute toxicity were 0.7 % and 2.0 %, 
respectively. With a median follow-up of 30 months (range: 
12-72), late GI ad GU toxicity were recorded in 4 and 18 pts, 
respectively. Based on IPSS score, no pts reported severe 
urinary symptoms, and 7.7% of pts reported moderate 
symptoms only. In terms of QoL, 91.3% declared to be 
“pleased”, 5.7% “mostly satisfied” and 1.3% “mixed” (1.7% 
not evaluable).  
 
Conclusion: Our experience confirms the safety of moderate 
hypofractionation delivered with IGRT/IMRT-SIB and a 
moderate impact on QoL in pts with PCa. Prolonged follow-up 
is needed to evaluate the results in terms of patients 
outcome. 
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Purpose or Objective: The aims of this prospective 
observational trial was to study early PSA kinetics by weekly 
PSA measurements during salvage radiotherapy (RT) for 
patients with recurrent prostate cancer in order to develop a 
predictive model for treatment outcome. 
 
Material and Methods: This prospective study included 
patients with a biochemical recurrence after prostatectomy 
referred for curative salvage RT. No previous or present anti-
hormonal treatment was allowed. All patients were 
prescribed 70 Gy in 35 fractions to the prostate bed. PSA was 
measured at baseline and then weekly during RT. A PSA 
follow-up was scheduled at 3, 6, 12, 18 and 24 months after 
RT and yearly thereafter. Treatment response was defined as 
PSA <0.1 ng/ml at these time points 
(PSA_RESP_3/6/12/18/24). Bivariate analyses of the 
association between response and clinical factors as well as 
PSA during RT were performed. Here we report the results 
for end-point PSA_RESP_6.  
 
Results: Since Sept 2012, 151 patients have reached six 
months follow-up after RT. PSA_RESP_6 was achieved in 89 
(59%) of the cases. Significant predictive clinical factors were 
proportion of positive biopsies, Gleason score, lymph node 
extirpation and surgical borders. However PSA during therapy 
was the single strongest predictive factor for PSA_RESP_6 
with a ROC AUC up to 0.92 (95% CI 0.86 – 0.95). 
 
Conclusion: We propose that PSA monitored during salvage 
RT can be used as a predictive factor for treatment outcome 
and subsequently for personalized patient management. 
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Purpose or Objective: There are different guide lines about 
delineating the post-operative prostatic fossa before EBRT. 
They all recommend that the patients should have a half full 
or comfortably filled bladder at the planning CT and at each 
fraction in order to ensure a consistent bladder volume 
throughout the whole treatment course. The aim of this 
study was to compare bladder volume variations between 1) 
a specific bladder filling protocol and 2) a simple instruction 
to the patients to keep a comfortably filled bladder before 
each treatment fraction. 
 
Material and Methods: Twenty-nine patients (median 65 y) 
with PSA-relapse planned for salvage radiation therapy were 
randomised in two groups, with different preparation 
instructions: 
1. Drinking 300 ml and empting the bladder one hour before 
planning CT and treatment fractions. (13 patients) 
2. A comfortably filled bladder before planning CT and 
treatment fractions. A pre-treatment drinking volume 
according to patient’s preference. (16 patients) 
Treatment was prescribed to 70 Gy/35/2. As a complement 
to positioning to bony anatomy a CBCT was performed once a 
week to calculate the bladder volumes. 
 
 
 
 
 
 
